During my two decades in the biotechnology industry and nearly a decade at Insilico, I’ve witnessed the destructive power of these changes, resulting in massive losses of decades and hundreds of billions of dollars in research efforts. Since I founded Insilico, pharma companies such as GSK, Novartis, and Sanofi have changed R&D executive leadership twice and Pfizer, Roche, BMS, Bayer, and Merck KGaA once.
I don’t follow Alex very closely, but I think Insilico’s business model is to identify drug targets using AI, and then partner with Pharma to further validate and bring those targets to market. The fact that he’s writing about this issue seems to suggest that perhaps Insilico’s business model is not working… You can complain about the market dynamics you are experiencing or you can adjust your business plan given the realities of the market. I suspect that later may be a more effective approach to running a business.
Or, maybe AI for drug finding isn’t ready for prime time:
3 Likes
